|
|
|
|
|
|
|
|
|
08.01.26 - 22:03
|
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues (GlobeNewswire EN)
|
|
|
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported preliminary, unaudited total revenue of $726.4 million for the year ended December 31, 2025, compared with $701.0 million for the year ended December 31, 2024. The company also repurchased 2.0 million shares of its common stock during the fourth quarter....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
26.11.25 - 22:03
|
Pacira BioSciences Files EXPAREL® Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical (GlobeNewswire EN)
|
|
|
-- Lawsuit triggers 30-month stay under the Hatch Waxman Act -- BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement lawsuit in the United States District Court for the District of Delaware against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. for patent infringement related to EXPAREL® (bupivacaine liposome injectable suspension)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.11.25 - 01:45
|
Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks)
|
|
|
Pacira (PCRX) delivered earnings and revenue surprises of +7.69% and -1.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
